CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical company and a leader in molecular chaperone regulation technology, today announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals. The paper’s authors, led by Stuart K. Calderwood, Ph.D., of Beth Israel Deaconess Medical Center, Harvard Medical School, reviewed 40 clinical and animal studies in peer-reviewed publications and found that molecular chaperones play an important role in the deterrence of protein damage during the aging process and that chaperone expression is required for cell longevity.
“This extensive review of scientific data from multiple clinicians provides independent verification of the considerable potential of molecular chaperones in designing pharmaceuticals to treat a multitude of age-related diseases and disorders. This opens new blockbuster opportunities for our molecular chaperone technology beyond the large neurodegenerative disease, stroke recovery and neuropathy markets that we have been investigating,” said CytRx’s President and CEO Steven A. Kriegsman. “The abstract’s conclusions add to the continually growing validation in the scientific literature of the tremendous commercial potential of our chaperone amplifying drug candidates. Several interested pharmaceutical suitors are currently evaluating potential partnerships aimed at advancing development of this technology, which will allow for greater internal focus on developing our considerable oncology assets.”